S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in

Novartis Stock Forecast, Price & News

+1.54 (+1.79 %)
(As of 03/1/2021 12:00 AM ET)
Today's Range
Now: $87.45
50-Day Range
MA: $91.87
52-Week Range
Now: $87.45
Volume1.64 million shs
Average Volume2.13 million shs
Market Capitalization$200.15 billion
P/E Ratio28.30
Dividend Yield2.34%
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Novartis logo


4 Healthcare Stocks to Buy and Hold for the Long Term
February 24, 2021 |  stocknews.com
Novartis Is Oversold
February 23, 2021 |  forbes.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year Founded1996



Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.40 per share
Book Value$24.53 per share


Net Income$11.73 billion


Outstanding Shares2,288,700,000
Market Cap$200.15 billion
Next Earnings Date4/27/2021 (Estimated)


Overall MarketRank

2.10 out of 5 stars

Medical Sector

40th out of 1,966 stocks

Pharmaceutical Preparations Industry

14th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
+1.54 (+1.79 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Novartis (NYSE:NVS) Frequently Asked Questions

Is Novartis a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis
or view top-rated stocks.

What stocks does MarketBeat like better than Novartis?

Wall Street analysts have given Novartis a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novartis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novartis?

Novartis saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 6,380,000 shares, an increase of 44.0% from the December 31st total of 4,430,000 shares. Based on an average daily trading volume, of 2,050,000 shares, the short-interest ratio is currently 3.1 days. Currently, 0.3% of the shares of the stock are short sold.
View Novartis' Short Interest

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Novartis

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings data on Monday, January, 25th. The company reported $1.34 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.37 by $0.03. The business had revenue of $12.77 billion for the quarter, compared to analyst estimates of $12.86 billion. Novartis had a trailing twelve-month return on equity of 24.39% and a net margin of 14.71%. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.32 EPS.
View Novartis' earnings history

How has Novartis' stock price been impacted by COVID-19 (Coronavirus)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVS stock has increased by 6.5% and is now trading at $87.45.
View which stocks have been most impacted by COVID-19

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Wednesday, January 27th. Stockholders of record on Friday, March 5th will be given a dividend of $3.3784 per share on Monday, March 15th. This represents a yield of 2.2%. The ex-dividend date is Thursday, March 4th. This is a positive change from Novartis's previous annual dividend of $3.04.
View Novartis' dividend history

Is Novartis a good dividend stock?

Novartis pays an annual dividend of $2.01 per share and currently has a dividend yield of 2.34%. Novartis does not yet have a strock track record of dividend growth. The dividend payout ratio of Novartis is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 30.83% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

What price target have analysts set for NVS?

10 equities research analysts have issued twelve-month target prices for Novartis' stock. Their forecasts range from $105.00 to $116.00. On average, they anticipate Novartis' stock price to reach $111.00 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Novartis
or view top-rated stocks among Wall Street analysts.

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 45) (LinkedIn Profile)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 56) (LinkedIn Profile)
  • Mr. Steffen Lang Ph.D., Global Head of Technical Operations (Age 54) (LinkedIn Profile)
  • Ms. Shannon Thyme Klinger, Chief Legal Officer (Age 50) (LinkedIn Profile)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 53) (LinkedIn Profile)
  • Mr. Steven Baert, Chief People & Organization Officer (Age 47) (LinkedIn Profile)
  • Mr. Bertrand J.F.X. Bodson, Chief Digital Officer (Age 46)
  • Dr. John Tsai, Head of Global Drug Devel. & Chief Medical Officer (Age 54)
  • Mr. Robert Weltevreden, Head of Novartis Bus. Services (Age 52)
  • Ms. Susanne Schaffert Ph.D., Pres of Novartis Oncology (Age 54) (LinkedIn Profile)

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (0.95%), Dodge & Cox (0.94%), Fisher Asset Management LLC (0.41%), Mawer Investment Management Ltd. (0.29%), Wells Fargo & Company MN (0.28%) and Boston Partners (0.26%).

Which major investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Mawer Investment Management Ltd., Primecap Management Co. CA, Price T Rowe Associates Inc. MD, Lazard Asset Management LLC, BlackRock Inc., Charles Schwab Investment Management Inc., and Boston Partners.

Which major investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Morgan Stanley, Everett Harris & Co. CA, Brandes Investment Partners LP, Principal Financial Group Inc., Principal Financial Group Inc., Allegiant Private Advisors LLC, and Voloridge Investment Management LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $87.45.

How much money does Novartis make?

Novartis has a market capitalization of $200.15 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis.

How many employees does Novartis have?

Novartis employs 110,000 workers across the globe.

Does Novartis have any subsidiaries?

The following companies are subsidiares of Novartis: Admune Therapeutics, Advanced Accelerator Applications, Alcon, Amblyotech, AveXis, CellforCure, Chiron Corporation, CoStim Pharmaceuticals, Corthera, Encore Vision, Endocyte, Fougera Pharmaceuticals, Hexal, Novartis Inflammasome Research, Protez Pharmaceuticals, Selexys Pharmaceuticals Corporation, Spinifex Pharmaceuticals, The Medicines Company, Vedere Bio, Xiidra, and Ziarco.

When was Novartis founded?

Novartis was founded in 1996.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

Where are Novartis' headquarters?

Novartis is headquartered at LICHTSTRASSE 35, BASEL V8, CH 4056.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.